AFT Pharmaceutical awarded R&D grant by Callaghan Innovation

AFT Pharmaceuticals has today been announced as a recipient of a government Technology Development Grant (TDG) by Callaghan Innovation.

The TDG grants are valued at 20% of the R&D spend of each business (up to a maximum of $2.4 million per year for three years). AFT Pharmaceuticals has been awarded a total of $3.85M to assist with R&D expenditure.

Dr Hartley Atkinson, Managing Director at AFT Pharmaceuticals, welcomed today’s announcement by Hon Steven Joyce, Minister of Science and Innovation.

“We are hugely appreciative of the government’s support. New and improved product development sits at the heart of this company,” said Dr Atkinson. “It drives us day-to-day and it’s allowed us to compete on the world stage in a very competitive industry. But R&D in the pharmaceutical space is very expensive, so we appreciate the government assisting with some of these costs. This money will help with a variety of trial work and will help us move faster in getting products to overseas markets.”

Read the Minister’s media release here.

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More